Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models

During the development of indazolylpyrimidines as novel and potent inhibitors of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR2) tyrosine kinase, we observed that some human tumour xenografts are more sensitive to VEGFR2 kinase inhibitors than others. A better understanding of the basi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Dev, I K, Dornsife, R E, Hopper, T M, Onori, J A, Miller, C G, Harrington, L E, Dold, K M, Mullin, R J, Johnson, J H, Crosby, R M, Truesdale, A T, Epperly, A H, Hinkle, K W, Cheung, M, Stafford, J A, Luttrell, D K, Kumar, R
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2004
Matèries:
Experimental Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409895/
https://ncbi.nlm.nih.gov/pubmed/15328520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602109
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars